Drug intelligence / Profile preview

CXCL-8 antisense vector

Development stage
Preclinical
Lead developer
University of Nebraska Medical Center
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration
Intramuscular
01

Overview

CXCL-8 antisense vector is a gene therapy approach designed to suppress the expression of C-X-C motif chemokine ligand 8 (CXCL-8), also known as Interleukin-8 (IL-8). CXCL-8 is a chemokine secreted by melanoma and stromal cells that acts as a growth and angiogenic factor, promoting tumor progression, invasion, and metastasis. By utilizing an antisense expression vector, researchers aim to knock down CXCL-8 levels, thereby inhibiting primary tumor growth and reducing metastatic potential. Preclinical studies in melanoma cell lines (such as A375SM) and mouse xenograft models have demonstrated that suppression of CXCL-8 leads to increased cell death and reduced microvessel density.

Other names
CXCL-8 antisense expression vectorCXCL8 antisense expression vectorCXCL 8 antisense expression vectorIL-8 antisense vectorIL8 antisense vectorIL 8 antisense vectorInterleukin-8 antisense vectorInterleukin8 antisense vectorInterleukin 8 antisense vector
02

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on CXCL-8 antisense vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXCL-8 antisense vector.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call